Position of the Transparency Council – Adderall XR (amphetamine/dextroamphetamine)

At its meeting on 16 September 2024, the Transparency Council adopted position No. 94/2024 on the appropriateness of issuing reimbursement approvals for the drug Adderall XR (amphetamine/dextroamphetamine) for the indication: treatment of attention deficit hyperactivity disorder (ADHD) (ICD-10: F90.1).

Publication of the position >>